Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 15/20 | 0.57 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5428616 | 0.92 | TRPV1 (0.61) | TRPV1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL5428633 | 0.90 | TRPV1 (0.58) | TRPV1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL5431058 | 0.90 | TRPV1 (0.58) | TRPV1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL5432639 | 0.88 | TRPV1 (0.55) | TRPV1RXFP1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5432627 | 0.86 | TRPV1 (0.61) | TRPV1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL5439678 | 0.86 | TRPV1 (0.58) | TRPV1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL5447620 | 0.84 | TRPV1 (0.56) | TRPV1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL5447576 | 0.84 | TRPV1 (0.54) | TRPV1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL5436030 | 0.83 | TRPV1 (0.49) | TRPV1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL5442775 | 0.83 | TRPV1 (0.70) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219203-A1 | Arylalkylamino-substituted quinazoline analogues | NEUROGEN CORPORATION (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219203-A1 | Arylalkylamino-substituted quinazoline analogues | NEUROGEN CORPORATION (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219203-A1 | Arylalkylamino-substituted quinazoline analogues | NEUROGEN CORPORATION (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219203-A1 | Arylalkylamino-substituted quinazoline analogues | PIGS, GPR35, HRH4 | TRPV1 358/4885PPARG 68/4885RXFP1 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.